XML 72 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6
ALLIANCES AND COLLABORATIONS (Otsuka) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Dec. 31, 2011
Sep. 30, 2012
ABILIFY [Member]
Sep. 30, 2011
ABILIFY [Member]
Sep. 30, 2012
ABILIFY [Member]
Sep. 30, 2011
ABILIFY [Member]
Sep. 30, 2012
Otsuka [Member]
ABILIFY [Member]
Sep. 30, 2011
Otsuka [Member]
ABILIFY [Member]
Sep. 30, 2012
Otsuka [Member]
ABILIFY [Member]
Sep. 30, 2011
Otsuka [Member]
ABILIFY [Member]
Sep. 30, 2012
Otsuka [Member]
ABILIFY [Member]
Upfront, milestone and other licensing payments [Member]
Sep. 30, 2011
Otsuka [Member]
ABILIFY [Member]
Upfront, milestone and other licensing payments [Member]
Sep. 30, 2012
Otsuka [Member]
ABILIFY [Member]
Upfront, milestone and other licensing payments [Member]
Sep. 30, 2011
Otsuka [Member]
ABILIFY [Member]
Upfront, milestone and other licensing payments [Member]
Dec. 31, 2011
Otsuka [Member]
ABILIFY [Member]
Upfront, milestone and other licensing payments [Member]
Sep. 30, 2012
Otsuka [Member]
ABILIFY, SPRYCEL and IXEMPRA [Member]
Sep. 30, 2011
Otsuka [Member]
ABILIFY, SPRYCEL and IXEMPRA [Member]
Sep. 30, 2012
Otsuka [Member]
ABILIFY, SPRYCEL and IXEMPRA [Member]
Sep. 30, 2011
Otsuka [Member]
ABILIFY, SPRYCEL and IXEMPRA [Member]
Sep. 30, 2012
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Sep. 30, 2011
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Sep. 30, 2012
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Sep. 30, 2011
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Dec. 31, 2012
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Dec. 31, 2011
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Sep. 30, 2012
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Extension payment [Member]
Sep. 30, 2011
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Extension payment [Member]
Sep. 30, 2012
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Extension payment [Member]
Sep. 30, 2011
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Extension payment [Member]
Dec. 31, 2011
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Extension payment [Member]
Apr. 30, 2009
Otsuka [Member]
United States [Member]
ABILIFY [Member]
Extension payment [Member]
Dec. 31, 2012
Otsuka [Member]
France, Germany, Spain, and United Kingdom [Member]
ABILIFY [Member]
Sep. 30, 2012
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Sep. 30, 2011
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Sep. 30, 2012
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Sep. 30, 2011
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Operating expense up to $175 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Operating expenses over $175 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Annual net sales up to $400 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Annual net sales between $400 and $600 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Annual net sales between $600 and $800 million [Member]
Dec. 31, 2012
Otsuka [Member]
Oncology Territory [Member]
SPRYCEL and IXEMPRA [Member]
Annual net sales over $800 million [Member]
Alliances and Collaborations Statement [Line Items]                                                                                          
Percentage of net sales recognized from collaboration                                                     51.50% 53.50%             65.00%                    
Percentage of operating expense reimbursements from collaboration                                                     30.00%                         20.00% 1.00%        
Payment to extend term of commercialization agreement                                                                   $ 400                      
Percentage of net sales payable to collaboration partner 1.50%   1.50%                                                                             30.00% 5.00% 3.00%  
Range of sales at which a given percentage will be paid to collaboration partner - maximum                                                                                   400 600 800  
Range of sales at which a given percentage will be paid to collaboration partner - minimum                                                                                     400 600 800
Amount of operating expense over which collaboration partner will reimburse given percentage                                                                               175 175        
ABILIFY* net sales, including amortization of extension payment 3,736 5,345 13,430 15,790   676 691 2,008 2,021 676 691 2,008 2,021                                                                
Oncology Products collaboration fee expense                                                                       36 30 103 100            
Royalty expense                                             18 18 55 52                                      
Commercialization expense reimbursement to/(from) Otsuka                                     (2) (15) (34) (37)                                              
Amortization (income)/expense - extension payment                                                         16 16 49 49                          
Amortization expense - upfront, milestone and other licensing payments     394 261                   1 1 5 5                                                        
Other assets - extension payment 877   877   824                                               170   170   219                        
Other intangible assets - upfront, milestone and other licensing payments $ 9,217   $ 9,217   $ 3,124                         $ 5